Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients.
Keiichi AkahoshiDaisuke BanRyo KubokiAtsushi ObaHiroaki OnoYusuke MitsunoriAtsushi KudoShinji TanakaMinoru TanabePublished in: Journal of gastroenterology and hepatology (2018)
Cholangiocarcinoma patients with high OPRT expression would benefit from postoperative adjuvant S-1 therapy, which increases the DFS. Assessment of OPRT expression may contribute to the optimization of adjuvant chemotherapy for cholangiocarcinoma.